Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

EGFR +
- Failed EGFR TKI
  - TKI 1st/3rd Generation
    - EGFR 19 or 21

LUN0123
- Phase II/II Selective RET Inhibitor
  - TAT0952/HS0852 in Advanced Solid Tumors w/ RET Gene Abnormalities
  - PI: Wakelee
  - Pending

LUN0122
- Phase II Carboplatin + Pemetrexed + Bevacizumab +/− Atezolizumab in Stage IV Non-Squamous NSCLC
  - PI: Wakelee
  - NCT03403966

LUN012
- Phase II Carboplatin + Pemetrexed + Bevacizumab +/− Atezolizumab in Stage IV Non-Squamous NSCLC
  - PI: Wakelee
  - NCT03722901

RET+

ALK +

KRAS G12 C+

MET/RET/ROS1

PTK7 + Study Screening

ECOG ACRIN-EA5181
- Phase II Cabozantinib +/- Nivolumab vs Standard Chemotherapy in Previously Treated Non-Squamous NSCLC
  - PI: Neal
  - ECOG-ACRIN

ECOG ACRIN-S1900-E
- Phase II AMG 510 in Previously Tx Stage IV or Recurrent KRAS G12C Mutated Non-Squamous NSCLC
  - PI: Neal
  - ECOG-ACRIN

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu